Dr. Patrick E. Prath, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 322
Licensed in Texas since 2019, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license S4548 (first issued 2019; active) -
Hematology (Internal Medicine) Physician
TX license S4548 (first issued 2019; active) -
Hematology & Oncology Physician
TX license S4548 (first issued 2019; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Houston Methodist Hospital Houston, TX
- Houston Methodist Sugarland Hospital Sugar Land, TX
- Houston Methodist West Hospital Houston, TX
- Houston Methodist Clear Lake Hospital Nassau Bay, TX
- Matagorda Regional Medical Center Bay City, TX
Medical groups
- Tmh Physician Associates PLLC (1,690 clinicians)
- Houston Methodist Specialty Physicians (1,528 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 322
- Services billed
- 1,281
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 333 | 143 |
| Established patient office or other outpatient visit, 20-29 minutes | 165 | 116 |
| Established patient office or other outpatient visit, 40-54 minutes | 86 | 55 |
| Telephone medical discussion with physician, 21-30 minutes | 64 | 51 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 50 | 50 |
| New patient office or other outpatient visit, 60-74 minutes | 48 | 48 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 48 | 28 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 47 | 37 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 41 | 39 |
| Telephone medical discussion with physician, 11-20 minutes | 41 | 40 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Sugar Land, TX | 211 |
| Abiraterone Acetate | 208 |
| Eliquis (apixaban) Other prescribers in Sugar Land, TX | 164 |
| Ondansetron Hcl Other prescribers in Sugar Land, TX | 87 |
| Xarelto (rivaroxaban) Other prescribers in Sugar Land, TX | 84 |
| Prochlorperazine Maleate Other prescribers in Sugar Land, TX | 63 |
| Dexamethasone Other prescribers in Sugar Land, TX | 61 |
| Hydroxyurea Other prescribers in Sugar Land, TX | 56 |
| Warfarin Sodium Other prescribers in Sugar Land, TX | 53 |
| Orgovyx (relugolix) | 48 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 26 companies reported 63 payments worth $1,755 in total to this clinician.
| Janssen Biotech, Inc. | $229 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $181 |
| E.r. Squibb & Sons, L.l.c. | $144 |
| Pfizer Inc. | $137 |
| Seagen Inc. | $99.95 |
| Celgene Corporation | $98.28 |
| Dendreon Pharmaceuticals LLC | $86.23 |
| Daiichi Sankyo Inc. | $76.55 |
| Food and Beverage | $1,565 |
|---|---|
| Education | $190 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Seagen Inc. Sep 30, 2025 | Education in-kind | $99.95 |
| Janssen Biotech, Inc. Dec 10, 2025 | Education ERLEADA · Oncology · in-kind | $90.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.